text: <unk>  is a Immune Modulator that is FDA approved for the treatment of Multiple myeloma(MM), Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS), Mantle cell lymphoma (MCL). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, neutropenia, constipation, diarrhea, muscle cramp, anemia, pyrexia, peripheral edema, nausea, back pain, upper respiratory tract infection, dyspnea, dizziness, thrombocytopenia, tremor and rash.
option_0: Lenalidomide
option_1: Ruxolitinib
option_2: Pomalidomide
option_3: Bortezomib
option_4: Rituximab
option_5: Ibrutinib
option_6: Dihydroergocristine
option_7: Alemtuzumab